Helix Days Sales Outstanding vs Free Cash Flow Yield Analysis

HBP Stock

CAD 0.95 0.05 5.00%

Helix BioPharma financial indicator trend analysis is much more than just examining Helix BioPharma Corp latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Helix BioPharma Corp is a good investment. Please check the relationship between Helix BioPharma Days Sales Outstanding and its Free Cash Flow Yield accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Days Sales Outstanding vs Free Cash Flow Yield

Days Sales Outstanding vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Helix BioPharma Corp Days Sales Outstanding account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Helix BioPharma's Days Sales Outstanding and Free Cash Flow Yield is -0.03. Overlapping area represents the amount of variation of Days Sales Outstanding that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Helix BioPharma Corp, assuming nothing else is changed. The correlation between historical values of Helix BioPharma's Days Sales Outstanding and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Sales Outstanding of Helix BioPharma Corp are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Days Sales Outstanding i.e., Helix BioPharma's Days Sales Outstanding and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.03

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Sales Outstanding

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Helix BioPharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Helix BioPharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Helix BioPharma's Discontinued Operations is very stable compared to the past year. As of the 17th of December 2024, Sales General And Administrative To Revenue is likely to grow to 1.36, while Selling General Administrative is likely to drop about 2.8 M.

	2023	2024 (projected)
Minority Interest	117K	111.2K
Reconciled Depreciation	14K	13.3K

Minority Interest Reconciled Depreciation

Helix BioPharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Property Plant Equipment	Non Currrent Assets Other
Total Assets		-0.07	-0.49	0.96	0.76	-0.95	0.87	-0.51	0.99	0.72	0.99	0.75	-0.69	0.03	0.77	-0.14	-0.16	-0.41	-0.18	1.0	0.13	0.95	0.7	-0.62	0.81	0.54
Other Current Liab	-0.07		-0.05	-0.01	0.17	-0.04	0.13	0.07	-0.12	0.16	-0.12	0.05	0.03	-0.44	0.26	-0.22	0.48	-0.14	0.07	-0.09	0.07	0.09	0.26	-0.22	0.24	0.19
Total Current Liabilities	-0.49	-0.05		-0.7	-0.43	0.66	-0.47	0.75	-0.48	-0.4	-0.48	-0.29	0.28	0.4	-0.23	0.26	0.35	0.96	0.23	-0.48	-0.23	-0.65	-0.12	0.1	-0.3	-0.33
Total Stockholder Equity	0.96	-0.01	-0.7		0.76	-0.98	0.86	-0.64	0.94	0.72	0.94	0.7	-0.64	-0.1	0.71	-0.16	-0.21	-0.64	-0.21	0.95	0.18	0.98	0.64	-0.58	0.77	0.55
Property Plant And Equipment Net	0.76	0.17	-0.43	0.76		-0.73	0.91	-0.22	0.65	0.98	0.65	0.88	-0.78	-0.19	0.84	-0.33	-0.19	-0.43	-0.34	0.7	0.18	0.78	0.58	-0.5	0.82	0.71
Net Debt	-0.95	-0.04	0.66	-0.98	-0.73		-0.85	0.53	-0.94	-0.67	-0.94	-0.65	0.65	0.18	-0.68	0.18	0.15	0.62	0.3	-0.95	-0.17	-0.97	-0.67	0.6	-0.79	-0.49
Retained Earnings	0.87	0.13	-0.47	0.86	0.91	-0.85		-0.31	0.81	0.84	0.81	0.9	-0.9	-0.08	0.74	-0.37	-0.2	-0.45	-0.47	0.84	0.28	0.86	0.62	-0.52	0.87	0.65
Accounts Payable	-0.51	0.07	0.75	-0.64	-0.22	0.53	-0.31		-0.55	-0.23	-0.55	-0.23	0.1	-0.14	-0.23	-0.05	0.23	0.66	-0.26	-0.53	-0.1	-0.61	-0.16	0.14	-0.16	-0.22
Cash	0.99	-0.12	-0.48	0.94	0.65	-0.94	0.81	-0.55		0.6	1.0	0.66	-0.64	0.07	0.67	-0.1	-0.15	-0.4	-0.16	1.0	0.1	0.93	0.67	-0.59	0.75	0.43
Non Current Assets Total	0.72	0.16	-0.4	0.72	0.98	-0.67	0.84	-0.23	0.6		0.6	0.85	-0.71	-0.19	0.87	-0.32	-0.22	-0.4	-0.26	0.65	0.12	0.73	0.52	-0.45	0.74	0.72
Cash And Short Term Investments	0.99	-0.12	-0.48	0.94	0.65	-0.94	0.81	-0.55	1.0	0.6		0.66	-0.64	0.07	0.67	-0.1	-0.15	-0.4	-0.16	1.0	0.1	0.93	0.67	-0.59	0.75	0.43
Net Receivables	0.75	0.05	-0.29	0.7	0.88	-0.65	0.9	-0.23	0.66	0.85	0.66		-0.87	0.15	0.73	-0.3	-0.2	-0.25	-0.37	0.7	0.47	0.71	0.54	-0.45	0.77	0.82
Common Stock Shares Outstanding	-0.69	0.03	0.28	-0.64	-0.78	0.65	-0.9	0.1	-0.64	-0.71	-0.64	-0.87		-0.05	-0.51	0.43	0.4	0.27	0.7	-0.66	-0.34	-0.61	-0.34	0.23	-0.67	-0.56
Non Current Liabilities Total	0.03	-0.44	0.4	-0.1	-0.19	0.18	-0.08	-0.14	0.07	-0.19	0.07	0.15	-0.05		-0.09	0.46	0.06	0.42	0.27	0.06	0.22	-0.11	-0.01	0.04	-0.08	0.07
Inventory	0.77	0.26	-0.23	0.71	0.84	-0.68	0.74	-0.23	0.67	0.87	0.67	0.73	-0.51	-0.09		-0.12	0.17	-0.21	0.04	0.72	0.03	0.77	0.78	-0.71	0.83	0.68
Other Current Assets	-0.14	-0.22	0.26	-0.16	-0.33	0.18	-0.37	-0.05	-0.1	-0.32	-0.1	-0.3	0.43	0.46	-0.12		0.41	0.14	0.39	-0.11	-0.1	-0.15	-0.01	0.01	-0.17	-0.19
Other Stockholder Equity	-0.16	0.48	0.35	-0.21	-0.19	0.15	-0.2	0.23	-0.15	-0.22	-0.15	-0.2	0.4	0.06	0.17	0.41		0.26	0.42	-0.14	0.02	-0.09	0.46	-0.42	0.24	0.0
Total Liab	-0.41	-0.14	0.96	-0.64	-0.43	0.62	-0.45	0.66	-0.4	-0.4	-0.4	-0.25	0.27	0.42	-0.21	0.14	0.26		0.3	-0.4	-0.23	-0.61	-0.12	0.1	-0.3	-0.33
Property Plant And Equipment Gross	-0.18	0.07	0.23	-0.21	-0.34	0.3	-0.47	-0.26	-0.16	-0.26	-0.16	-0.37	0.7	0.27	0.04	0.39	0.42	0.3		-0.16	-0.38	-0.14	0.1	-0.15	-0.24	-0.23
Total Current Assets	1.0	-0.09	-0.48	0.95	0.7	-0.95	0.84	-0.53	1.0	0.65	1.0	0.7	-0.66	0.06	0.72	-0.11	-0.14	-0.4	-0.16		0.13	0.94	0.7	-0.62	0.78	0.49
Intangible Assets	0.13	0.07	-0.23	0.18	0.18	-0.17	0.28	-0.1	0.1	0.12	0.1	0.47	-0.34	0.22	0.03	-0.1	0.02	-0.23	-0.38	0.13		0.15	0.1	-0.08	0.26	0.7
Net Tangible Assets	0.95	0.09	-0.65	0.98	0.78	-0.97	0.86	-0.61	0.93	0.73	0.93	0.71	-0.61	-0.11	0.77	-0.15	-0.09	-0.61	-0.14	0.94	0.15		0.73	-0.67	0.83	0.54
Deferred Long Term Liab	0.7	0.26	-0.12	0.64	0.58	-0.67	0.62	-0.16	0.67	0.52	0.67	0.54	-0.34	-0.01	0.78	-0.01	0.46	-0.12	0.1	0.7	0.1	0.73		-0.98	0.89	0.46
Long Term Investments	-0.62	-0.22	0.1	-0.58	-0.5	0.6	-0.52	0.14	-0.59	-0.45	-0.59	-0.45	0.23	0.04	-0.71	0.01	-0.42	0.1	-0.15	-0.62	-0.08	-0.67	-0.98		-0.81	-0.41
Property Plant Equipment	0.81	0.24	-0.3	0.77	0.82	-0.79	0.87	-0.16	0.75	0.74	0.75	0.77	-0.67	-0.08	0.83	-0.17	0.24	-0.3	-0.24	0.78	0.26	0.83	0.89	-0.81		0.63
Non Currrent Assets Other	0.54	0.19	-0.33	0.55	0.71	-0.49	0.65	-0.22	0.43	0.72	0.43	0.82	-0.56	0.07	0.68	-0.19	0.0	-0.33	-0.23	0.49	0.7	0.54	0.46	-0.41	0.63

Click cells to compare fundamentals

Helix BioPharma Account Relationship Matchups

Helix BioPharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.9M	4.1M	3.7M	1.0M	1.5M	1.4M
Other Current Liab	350K	380K	344K	1.4M	724K	569.3K
Total Current Liabilities	1.9M	3.9M	3.4M	1.9M	1.6M	2.2M
Total Stockholder Equity	2.4M	(1.4M)	319K	(844K)	(90K)	(85.5K)
Property Plant And Equipment Net	246K	47K	35K	33K	29.7K	28.2K
Net Debt	(4.1M)	47K	(784K)	(808K)	(1.1M)	(1.1M)
Retained Earnings	(180.5M)	(188.6M)	(195.1M)	(201.4M)	(210.7M)	(221.2M)
Accounts Payable	1.4M	1.5M	599K	493K	855K	1.1M
Cash	4.2M	3.6M	3.3M	808K	1.1M	1.0M
Non Current Assets Total	246K	47K	35K	33K	29.7K	28.2K
Cash And Short Term Investments	4.2M	3.6M	3.3M	808K	1.1M	1.0M
Net Receivables	180K	353K	280K	62K	54K	51.3K
Common Stock Shares Outstanding	25.5M	27.6M	29.9M	38.6M	44.5M	46.7M
Liabilities And Stockholders Equity	4.9M	4.1M	3.7M	1.0M	1.5M	1.4M
Other Current Assets	245K	100K	443K	126K	321K	203.3K
Other Stockholder Equity	25.5M	27.9M	37.6M	48.5M	52.0M	31.7M
Total Liab	1.9M	5.5M	3.4M	1.9M	1.6M	2.4M
Property Plant And Equipment Gross	246K	1.8M	1.8M	1.8M	1.8M	1.9M
Total Current Assets	4.7M	4.0M	3.7M	996K	1.5M	1.4M
Accumulated Other Comprehensive Income	20.1M	19.6M	10.3M	4.4M	5.0M	2.8M
Net Tangible Assets	(3.3M)	2.4M	(1.4M)	319K	287.1K	272.7K
Property Plant Equipment	246K	47K	36K	33K	29.7K	28.2K
Non Currrent Assets Other	(3.0)	(1.0)	0.0	1K	900.0	855.0
Common Stock	137.3M	139.7M	147.5M	152.1M	158.6M	131.0M
Capital Surpluse	25.5M	27.9M	37.6M	44.1M	50.8M	29.9M
Current Deferred Revenue	38K	124K	301K	345K	396.8K	416.6K
Net Invested Capital	2.4M	2.2M	2.8M	(844K)	(90K)	(85.5K)
Net Working Capital	2.7M	144K	284K	(878K)	(123K)	(129.2K)
Capital Stock	137.3M	139.7M	147.5M	152.1M	158.6M	155.6M

Pair Trading with Helix BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Helix Stock

0.76	RY-PM	Royal Bank	Pair Corr
0.73	RY-PS	Royal Bank	Pair Corr
0.69	TD-PFI	Toronto Dominion Bank	Pair Corr
0.62	BNS	Bank of Nova Scotia	Pair Corr
0.61	TD-PFD	Toronto Dominion Bank	Pair Corr

The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.

The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Helix Stock

Balance Sheet is a snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Helix BioPharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Helix BioPharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Helix currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Helix Days Sales Outstanding vs Free Cash Flow Yield Analysis

Days Sales Outstanding vs Free Cash Flow Yield

Days Sales Outstanding vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Days Sales Outstanding

Free Cash Flow Yield

Helix BioPharma fundamental ratios Correlations

Helix BioPharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Helix BioPharma fundamental ratios Accounts

Pair Trading with Helix BioPharma

Moving against Helix Stock

Other Information on Investing in Helix Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Long Term Investments	- 0.98	Deferred Long Term Liab
Net Debt	- 0.98	Total Stockholder Equity
Net Tangible Assets	- 0.97	Net Debt
Total Current Assets	- 0.95	Net Debt
Net Debt	- 0.95	Total Assets
Cash And Short Term Investments	- 0.94	Net Debt